Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens

被引:2
|
作者
Hariri, Nosaibah [1 ]
Hasteh, Farnaz [1 ]
Walavalkar, Vighnesh [1 ]
Roma, Andres A. [1 ]
Fadare, Oluwole [1 ]
机构
[1] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
关键词
repeat testing; estrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; IN-SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; CORE-NEEDLE; CLINICAL ONCOLOGY/COLLEGE; PROTEIN EXPRESSION; AMERICAN SOCIETY; HER2; DISCORDANCE; ER; RECOMMENDATIONS;
D O I
10.1097/PAI.0000000000000525
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
At some tertiary breast care centers, where many patients are referred from other institutions, it is routine to repeat testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) in excision specimens if these tests were performed on the preceding biopsy at the referring facility. The goal of this study is to assess the value of this practice. We documented results from ER, PR, and HER2 testing in 541 consecutive invasive breast cancers excised over a 2.5-year period and analyzed the subset (n=153) for which testing was performed on the excision specimen solely due to the fact that testing on the preceding biopsy was performed at an outside institution. The rates and directions of biopsy-to-excision change were as follows: ER [1.3% (2/153), 100% from (+) to (-)]; PR [4% (6/153), 83% from (+) to (-)]; HER2/neu assessed by immunohistochemistry [21% (29/137)]; HER2/neu assessed by fluorescence in situ hybridization [3.3% (2/61); 50% from amplified to nonamplified and 50% vice versa]. There were no ER(-) and PR(-) biopsy cases that became ER and/or PR(+) in the excision. By coordinate analysis for the hormone receptors [ie, ER and/or PR(+) being indicative of "hormone receptor" (HR) positivity], there were no cases that changed from HR(+) in the biopsy to HR(-) in the excision (or vice versa), which suggests that repeat testing for ER and PR in this setting is of limited value. In an analysis that incorporated both immunohistochemistry and in situ fluorescence hybridization results, there were 2 cases with a clinically significant biopsy-to-excision change in HER2/neu status in which that change was detected primarily because the excision was retested. These findings provide baseline data for formulating policies on whether repeat testing should routinely be performed in the described scenario.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [41] Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer
    Chen, Mengdi
    Wu, Jiayi
    Liu, Deyue
    Chen, Weilin
    Lin, Caijin
    Andriani, Lisa
    Ding, Shuning
    Huang, Ou
    He, Jianrong
    Chen, Xiaosong
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    Zhu, Li
    CLINICAL BREAST CANCER, 2022, 22 (02) : E147 - E156
  • [42] Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer
    Yamamoto-Ibusuki, Mutsuko
    Yamamoto, Yutaka
    Yamamoto, Satoko
    Fujiwara, Saori
    Fu, Peifen
    Honda, Yumi
    Iyama, Ken-ichi
    Iwase, Hirotaka
    MODERN PATHOLOGY, 2013, 26 (01) : 79 - 86
  • [43] p16 promoter methylation, expression, and its association with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 subtype of breast carcinoma
    Goyal, Aditi
    Sahu, Ram Krishna
    Kumar, Mohit
    Sharma, Sonal
    Qayyum, Shariq
    Kaur, Navneet
    Singh, Usha Rani
    Mehrotra, Ravi
    Hedau, Suresh
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (05) : 1147 - 1154
  • [44] Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria
    Ajani, Mustapha Akanji
    Lawan, Aliyu
    Oke, Temitope
    Khramtsova, Galina
    Nwanji, Ifeanyichukwu
    Salami, Ayodeji
    Awolude, Olutosin
    Ebili, Henry
    Onwukamuche, Michael E.
    Sveen, Elisabeth
    Yoshimatsu, Toshio
    Olopade, Olufunmilayo, I
    AFRICAN HEALTH SCIENCES, 2023, 23 (03) : 236 - 244
  • [45] Immunohistochemical Detection of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression in Breast Carcinomas Comparison on Cell Block, Needle-Core, and Tissue Block Preparations
    Hanley, Krisztina Z.
    Birdsong, George G.
    Cohen, Cynthia
    Siddiqui, Momin T.
    CANCER CYTOPATHOLOGY, 2009, 117 (04) : 279 - 288
  • [46] Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years
    Alsughayer, Anas M.
    Dabbagh, Tamara Z.
    Abdel-Razeq, Rashid H.
    Al-Jussani, Ghada N.
    Alhassoon, Salam
    Sughayer, Maher A.
    JCO GLOBAL ONCOLOGY, 2022, 8
  • [47] Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases
    Yamanouchi, Kosho
    Kuba, Sayaka
    Eguchi, Susumu
    SURGERY TODAY, 2020, 50 (07) : 657 - 663
  • [48] Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer
    Geng, Yiting
    Chen, Xiaofeng
    Qiu, Jinrong
    Zhou, Yue
    Wang, Jian
    Liu, Lingxiang
    Shao, Yongfeng
    Yin, Yongmei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (02) : 303 - 311
  • [49] Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario
    Marshall, Deborah A.
    Ferrusi, Ilia L.
    Trudeau, Maureen
    Leighl, Natasha B.
    Hoch, Jeffrey S.
    Grazziotin, Luiza R.
    Khong, Hoa
    Pullenayegum, Eleanor
    Earle, Craig C.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) : 379 - 385
  • [50] Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
    Laokulrath, Natthawadee
    Gudi, Mihir
    Salahuddin, Syed Ahmed
    Chong, Angela Phek Yoon
    Ding, Cristine
    Iqbal, Jabed
    Leow, Wei Qiang
    Tan, Benjamin Yongcheng
    Tse, Gary
    Rakha, Emad
    Tan, Puay Hoon
    HISTOPATHOLOGY, 2024, 85 (03) : 371 - 382